01/06/2023 - General information
The genomics service of FIMIM, MARGenomics, has recently incorporated the Applied Biosystems GeneChip 3000 Dx v2, a cutting-edge microarray platform funded by the Carlos III Health Institute (ISCIII) and the European Union's NextGenerationEU program. The GeneChip 3000 Dx v2 system holds the distinction of being the first microarray platform in Europe and the United States with regulatory authorization for diagnostic use, thanks to its IVD-R (In Vitro Diagnosis Regulation) certification. This significant development has enabled us to enhance our microarray services by introducing a platform specifically designed for diagnostic purposes, while continuing to offer our traditional gene expression microarray services for experimental research.
Més informació "MARGenomics launches a new microarray platform with IVD-R certification"
02/05/23 - Institutional news
The Anti-Doping Laboratory of Catalonia was visited last week by a delegation of the Board of Directors of the Catalan Association of Sports Directors (ACDE). ACDE is an association that brings together leaders, federations and professionals in the world of sport in Catalonia while providing them with the best tools to develop their role and promote excellence in the management and values of sport. The delegation was formed by Pere Sust (President of ACDE), Jordi Durá (Secretary), Francisco Sanahuja, Miquel Torres, Pilar Xifré, Manuel Martínez and Judith Martínez, all of them with extensive and recognized links to Catalan and international sports federations and organizations, and was received by the IMIM management and the Laboratory management. After an introduction of the activities of IMIM and the Laboratory, the attendees visited the Laboratory facilities
18/05/2023 - General information
The PROMES-U project aims to improve the mental health of undergraduate students by analyzing the factors that may influence the onset of mental health problems, as well as the implementation and evaluation of online interventions for the promotion of mental health and the prevention of depression and anxiety problems. Follow-up data collection began last May 4 among students who filled out the baseline survey just one year ago, with an email being sent to those who gave up their email address. Upon completion of the questionnaire, they receive a personalized report on their mental health, as well as recommendations on healthy habits and available resources. The data collected will help to improve knowledge about the mental health of students at the university.
Més informació "Data collection is started with the PROMES-U follow-up questionnaire."
30/03/2023 - Press release
Adding a peptide, a molecule made of several amino acids, to oxaliplatin, a chemotherapy drug used to treat colorectal cancer, avoids the side effects this treatment can have on normal cells, including potential chemotherapy resistance. This is confirmed by an article published in the Journal of Medicinal Chemistry, led by the Hospital del Mar Medical Research Institute and the Institute for Research in Biomedicine (IRB Barcelona). This work is the second part of a recent study that explored how platinum accumulation in normal cells promotes platinum resistance in colorectal cancer cells. This new approach prevents healthy cells surrounding the tumour from accumulating platinum. This avoids the activation of certain genes linked to poor treatment response and tumour progression.
23/03/2023 - General information
The Associació Catalana de Gestors Esportius Professionals has recognized the international projection of the Laboratory. The Associació Catalana de Gestors Esportius Professionals (ACGEP) has awarded the Catalonia Prize for Sports Management on a national or international level to the Catalonian Anti-Doping Laboratory of the Hospital del Mar Medical Research Institute. The award recognizes the role of the Laboratory in projecting Catalonia to the world, its professionalism and its contribution to a cleaner sport. It was also highlighted that it is one of the thirty laboratories accredited in the world by the World Anti-Doping Agency to carry out doping controls on athletes, and that it works for clean sport in various national and international events.
01/03/2023 - Press release
Low levels of a particular protein in squamous cell carcinoma cells indicate that they are preparing to start migrating to other organs, thereby causing the tumour to spread to other areas of the body. This is according to a study by the Hospital del Mar Medical Research Institute, which has just been published in the journal Life Science Alliance. Tumour cells prepare to migrate by changing their metabolism so that they can consume lipids, in other words, cholesterol molecules. This raises the possibility of studying ways to block this process and prevent tumour metastasis.
Més informació "Marker discovered that shows when a type of skin cancer is preparing to metastasise"
24/02/2023 - Institutional news
It is led by Dr. Mario Cáceres, ICREA researcher who joins IMIM-Hospital del Mar in its talent attraction program. The group focuses on the application of the latest techniques in the field of genomics to analyze the relationship between changes in the genome and various fields of health. Dr. Mario Cáceres joins IMIM-Hospital del Mar heading a new research group, the Comparative and Functional Genomics Research Group. The arrival of Dr. Cáceres Aguilar, ICREA researcher, has come about thanks to the talent attraction program launched at the institution to boost the research carried out with top-level researchers.
23/02/2023 - Institutional news
The Associació Catalana de Dirigents de l'Esport (ACDE) awarded the distinction of Best Professional Leader to Dr. Rosa Ventura Alemany, director of the Anti-Doping Laboratory of Catalonia of the Hospital del Mar Institute of Medical Research. The distinction recognizes her work leading the Laboratory, one of the 30 laboratories accredited by the World Anti-Doping Agency in the world, and as coordinator of the Research Group on doping control in sport. It also recognizes the Laboratory's work in conducting doping controls for the 2018 Mediterranean Games in Tarragona, and in the management of athletes' biological passports. Finally, it recognizes the relevant scientific results achieved in recent years by the Research Group coordinated by Dr. Ventura Alemany.
21/02/2023 - Press release
A study led by researchers at the Hospital del Mar Medical Research Institute shows that the oxaliplatin administered in some cases of colorectal cancer accumulates in non-cancerous/healthy cells from the tumor environment. This accumulation causes healthy cells to produce a protein that further activates them, triggering tumor resistance to treatment and assisting in tumor regeneration. The researchers discovered a marker that can identify these tumors unresponsive to chemotherapy. The study, published in the journal Nature Communications, paves the way for new strategies enhancing the effects of chemotherapy on cancer cells while avoiding adverse side effects on non-cancerous cells.
06/02/2023 - Institutional news
The Hospital del Mar Medical Research Institute will lead one of the studies and will also be one of the main partners in the other three. They will receive funding from the European Union's Horizon Europe program. The LIVERATION project, led by surgeons and researchers from IMIM-Hospital del Mar and Hospital del Mar, will analyse the capacity of state-of-the-art radiofrequency equipment to widen resection margins in liver tumour removal surgery The other projects will explore treatment personalisation after surgery for localised colon cancer (Sagittarius); strategies for reducing childhood obesity in the European Union (OBELISK); and the use of innovative community interventions and new technologies to protect the mental health of Europeans (MENTBEST)
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact